GHK-Cu

A copper-binding tripeptide central to tissue regeneration and skin repair.

Written by Anthivera EditorialPending medical review

Updated Regulatory status verified May 1, 2026

Research-only

Relevance for women

Strong topical/cosmetic evidence for skin firmness, hydration, and post-procedure recovery. Injectable forms were placed in FDA Category 2 in 2023 and remain under review as of May 2026.

Recent research mentioning GHK-Cu

Pulled from our weekly editorial digest of PubMed, FDA, NEJM, JAMA, and Endpoints — cite-worthy entries only.

Where the evidence sits

Anthivera’s calibrated five-tier scale — what the strongest evidence on GHK-Cu actually supports today.

  1. Preclinical
  2. Limited clinical
  3. Multiple human studiesGHK-Cu
  4. Phase 3
  5. FDA-approved

Multiple human studies: Cohort or observational meta-analyses, or phase 1/2 RCTs.

Regulatory timeline

Dated milestones in GHK-Cu’s U.S. regulatory path.

  1. Late 2023

    Placed on FDA Category 2 (do-not-compound list), restricting compounding-pharmacy access.

  2. April 23, 2026

    Removed from FDA Category 2 compounding list. Removal is NOT the same as Category 1 status or FDA approval.

  3. July 23–24, 2026

    Pharmacy Compounding Advisory Committee (PCAC) review scheduled to evaluate inclusion on the 503A Bulks List.

Questions to bring to a consult

  1. 01What evidence is there for GHK-Cu in women specifically — and does that include perimenopausal or postmenopausal cohorts?
  2. 02What is the current FDA regulatory status, and which compounding pharmacy will my prescription go through?
  3. 03What baseline labs do you require before starting, and how often do you monitor?
  4. 04What are the realistic timelines and what does “not working for you” look like in practice?

Articles on GHK-Cu

Providers that offer GHK-Cu

See the full provider comparison for all peptides side by side.

Related peptides in skin & collagen